Management of the National Medical Research Center for Transplantology and Artificial Organs named after. acad. IN AND. Shumakov made an attempt to extinguish the conflict that broke out in connection with the closure of the transplantation department at the National Medical Research Center for Children’s Health. The director of the center, academician Sergei Gauthier, instructed to place an announcement on the official website of the institution for parents of children in need of a kidney transplant and pediatricians about their readiness to provide the necessary medical care to young patients.
“At the National Medical Research Center of TIO named after. ak. IN AND. Shumakov perform kidney transplants for children starting from the first year of life. Our center, in particular, has unique experience not only in kidney transplants, but also in simultaneous (double) transplants of various organs to children (including liver and kidney), as well as transplantations from blood group incompatible donors. Organ transplants are performed both from related (living) donors and from posthumous donors,” the statement says.
As confirmed to the Medvestnik.ru portal by the head of surgical department No. 1 (kidney transplant) of the center named after. ak. IN AND. Shumakova Igor Miloserdov, this initiative is partly explained by the desire to relieve the tension caused by the closure of the transplantology department at the National Medical Research Center for Children’s Health: “We have been doing such operations for a long time and are ready to take on an additional flow. On average, we perform a little more than 20 pediatric kidney transplants a year, this year there may be about 30. We don’t turn anyone away,” he emphasized.
At the National Medical Research Center named after. acad. IN AND. Shumakov, such transplantations are carried out in accordance with national clinical guidelines, the specialist noted. As the Pravmir portal previously reported, the reason for the closure of the transplantation department at the National Medical Research Center for Children’s Health was that its team used a new induction immunosuppression regimen based on the use of alemtuzumab. “No one in the world does this,” said Igor Miloserdov.
According to him, the transplant program at the National Medical Research Center for Children’s Health will continue, but with the participation of other specialists.